Chicago based crypto derivatives exchange Bitnomial has launched monthly futures contracts tied to Injective (INJ), marking the first US-regulated derivatives product linked to the token. The contracts settle directly in INJ and feature monthly expiries, enabling traders to gain price exposure without holding the underlying asset.
The futures can be margined in both cryptocurrency and US dollars through Bitnomial’s clearinghouse. Institutional clients have already been granted access, while retail participation is expected to roll out soon through the Botanical trading platform. The exchange also confirmed plans to introduce perpetual futures and options contracts tied to INJ in the future.

Bitnomial operates a fully integrated trading venue, brokerage and clearinghouse regulated by the Commodity Futures Trading Commission, reinforcing compliance within the evolving US crypto market.
ETF Eligibility and Injective Ecosystem Growth
The launch begins a six-month performance track record, a key requirement that could support a potential spot ETF tied to Injective. Earlier, Canary Capital filed for a staked INJ ETF, with Cboe BZX Exchange submitting a related rule change to the US Securities and Exchange Commission.
Injective (INJ) runs on a Layer 1 blockchain designed for financial applications, featuring an on-chain order book and cross-chain compatibility with networks such as Ethereum (ETH) and Solana (SOL).
Expanding Altcoin Futures Competition in the United States
Previous regulatory tensions also shaped the market. In August 2024, Bitnomial attempted to list XRP (XRP) futures through self-certification, but faced challenges from the US Securities and Exchange Commission. After filing a lawsuit in October 2025, the company later dropped the case in March and proceeded to launch regulated XRP futures as regulatory guidance evolved.
Disclaimer
This content is for informational purposes only and does not constitute financial, investment, or legal advice. Cryptocurrency trading involves risk and may result in financial loss.

